IN2015DN01900A - - Google Patents
Info
- Publication number
- IN2015DN01900A IN2015DN01900A IN1900DEN2015A IN2015DN01900A IN 2015DN01900 A IN2015DN01900 A IN 2015DN01900A IN 1900DEN2015 A IN1900DEN2015 A IN 1900DEN2015A IN 2015DN01900 A IN2015DN01900 A IN 2015DN01900A
- Authority
- IN
- India
- Prior art keywords
- disorders
- formula
- tautomers
- prodrugs
- variables
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261702005P | 2012-09-17 | 2012-09-17 | |
US201261702371P | 2012-09-18 | 2012-09-18 | |
PCT/EP2013/069173 WO2014041175A1 (en) | 2012-09-17 | 2013-09-16 | Novel inhibitor compounds of phosphodiesterase type 10a |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN01900A true IN2015DN01900A (zh) | 2015-08-07 |
Family
ID=49226152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1900DEN2015 IN2015DN01900A (zh) | 2012-09-17 | 2013-09-16 |
Country Status (19)
Country | Link |
---|---|
US (1) | US9388180B2 (zh) |
EP (1) | EP2895489B1 (zh) |
JP (1) | JP2015528484A (zh) |
KR (1) | KR20150056844A (zh) |
CN (1) | CN105102461A (zh) |
AR (1) | AR092595A1 (zh) |
AU (1) | AU2013314244A1 (zh) |
BR (1) | BR112015005935A2 (zh) |
CA (1) | CA2883910A1 (zh) |
HK (1) | HK1206728A1 (zh) |
IL (1) | IL237626A0 (zh) |
IN (1) | IN2015DN01900A (zh) |
MX (1) | MX2015003419A (zh) |
RU (1) | RU2015114331A (zh) |
SG (1) | SG11201502074YA (zh) |
TW (1) | TW201418264A (zh) |
UY (1) | UY35036A (zh) |
WO (1) | WO2014041175A1 (zh) |
ZA (1) | ZA201501458B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104640850A (zh) | 2012-10-26 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 3,4-二取代的1h-吡唑和4,5-二取代的噻唑的syk抑制剂 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
CN111592495A (zh) * | 2020-07-06 | 2020-08-28 | 上海启讯医药科技有限公司 | 一种2-正丁基-4-氯-5甲酰基咪唑的制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
US7057042B2 (en) * | 2002-05-29 | 2006-06-06 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
JP2007508241A (ja) | 2003-07-31 | 2007-04-05 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Pde10a阻害剤を用いる糖尿病および関連障害の処置方法 |
BRPI0511854A (pt) | 2004-06-07 | 2008-01-15 | Pfizer Prod Inc | inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica |
WO2006028957A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
RU2380101C2 (ru) * | 2004-09-30 | 2010-01-27 | Тиботек Фармасьютикалз Лтд. | Бициклические пиримидины, ингибирующие hcv |
WO2007022280A1 (en) | 2005-08-16 | 2007-02-22 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
JP2009524637A (ja) | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
JP2009527560A (ja) | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ10阻害剤としてのシンノリン誘導体 |
MX2008010671A (es) | 2006-02-21 | 2008-10-01 | Amgen Inc | Derivados de cinolina como inhibidores de fosfodiesterasa 10. |
CA2641670A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
EP1991531A1 (en) | 2006-02-28 | 2008-11-19 | Amgen Inc. | Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors |
US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
CA2644850A1 (en) | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
WO2008001182A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
WO2008006372A1 (en) | 2006-07-10 | 2008-01-17 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl- thiomorpholin-4-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline |
WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
US20090062291A1 (en) | 2007-08-22 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
WO2009070583A1 (en) | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
WO2009068320A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
JP2011505366A (ja) * | 2007-11-30 | 2011-02-24 | ワイス・エルエルシー | ホスホエステラーゼ10の阻害剤としてのアリールおよびヘテロアリール縮合イミダゾ[1,5−a]ピラジン |
MY161369A (en) | 2008-06-10 | 2017-04-14 | Abbvie Inc | Novel tricyclic compounds |
WO2010054260A1 (en) * | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
WO2011008597A1 (en) | 2009-07-14 | 2011-01-20 | Schering Corporation | Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors |
US8361962B2 (en) | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
-
2013
- 2013-09-16 JP JP2015531593A patent/JP2015528484A/ja not_active Withdrawn
- 2013-09-16 WO PCT/EP2013/069173 patent/WO2014041175A1/en active Application Filing
- 2013-09-16 CN CN201380048224.3A patent/CN105102461A/zh active Pending
- 2013-09-16 KR KR1020157009897A patent/KR20150056844A/ko not_active Application Discontinuation
- 2013-09-16 MX MX2015003419A patent/MX2015003419A/es unknown
- 2013-09-16 EP EP13765695.5A patent/EP2895489B1/en not_active Not-in-force
- 2013-09-16 BR BR112015005935A patent/BR112015005935A2/pt not_active IP Right Cessation
- 2013-09-16 AU AU2013314244A patent/AU2013314244A1/en not_active Abandoned
- 2013-09-16 SG SG11201502074YA patent/SG11201502074YA/en unknown
- 2013-09-16 IN IN1900DEN2015 patent/IN2015DN01900A/en unknown
- 2013-09-16 RU RU2015114331A patent/RU2015114331A/ru not_active Application Discontinuation
- 2013-09-16 CA CA2883910A patent/CA2883910A1/en not_active Abandoned
- 2013-09-17 UY UY0001035036A patent/UY35036A/es not_active Application Discontinuation
- 2013-09-17 AR ARP130103326A patent/AR092595A1/es unknown
- 2013-09-17 TW TW102133710A patent/TW201418264A/zh unknown
- 2013-09-17 US US14/029,142 patent/US9388180B2/en active Active
-
2015
- 2015-03-03 ZA ZA2015/01458A patent/ZA201501458B/en unknown
- 2015-03-09 IL IL237626A patent/IL237626A0/en unknown
- 2015-07-28 HK HK15107215.7A patent/HK1206728A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN105102461A (zh) | 2015-11-25 |
KR20150056844A (ko) | 2015-05-27 |
UY35036A (es) | 2014-03-31 |
AU2013314244A1 (en) | 2015-03-12 |
IL237626A0 (en) | 2015-04-30 |
ZA201501458B (en) | 2018-11-28 |
US9388180B2 (en) | 2016-07-12 |
MX2015003419A (es) | 2015-09-23 |
AU2013314244A8 (en) | 2015-04-30 |
EP2895489A1 (en) | 2015-07-22 |
JP2015528484A (ja) | 2015-09-28 |
HK1206728A1 (zh) | 2016-01-15 |
AR092595A1 (es) | 2015-04-29 |
WO2014041175A1 (en) | 2014-03-20 |
SG11201502074YA (en) | 2015-05-28 |
TW201418264A (zh) | 2014-05-16 |
EP2895489B1 (en) | 2017-10-18 |
BR112015005935A2 (pt) | 2017-07-04 |
RU2015114331A (ru) | 2016-11-10 |
CA2883910A1 (en) | 2014-03-20 |
US20140107126A1 (en) | 2014-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015012008A (es) | Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a. | |
AU2012277802A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
TN2015000368A1 (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
MD20160078A2 (ro) | Inhibitori ai Syk | |
PH12015500488A1 (en) | Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
TN2013000285A1 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
PH12015501962A1 (en) | Novel inhibitor compounds of phosphodiesterase type 10a | |
MX2012001070A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos. | |
GEP201706748B (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
MY182559A (en) | Process for the preparation of a pde4 inhibitor | |
BR112015009649A2 (pt) | composto de triazolo | |
MX2014011354A (es) | Compuestos de piridopirimidina sustituida y su uso como inhibidores de tirosina cinasa 3 similar a fms. | |
WO2011107608A8 (en) | Heterocyclic amides as rock inhibitors | |
PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
IN2015DN01900A (zh) | ||
MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
MX2013003202A (es) | Inhibidores de oxadiazol de la produccion de leucotrienos. | |
MX2015006539A (es) | Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a. | |
MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. |